Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38663402 | 0.90 | HDAC4 (0.47) | HTTALOX5SIGMAR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL755827 | 0.85 | HTT (0.59) | HTTALOX5SIGMAR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL13226836 | 0.84 | HDAC4 (0.49) | ALOX5SIGMAR1ALDH1A1SMN1; SMN2HDAC4 | |
| SCHEMBL8064820 | 0.84 | HDAC4 (0.49) | ALOX5CTBP2HDAC4HDAC6POLB | |
| SCHEMBL8371453 | 0.84 | HDAC4 (0.49) | HTTALOX5SIGMAR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL8052668 | 0.83 | HDAC4 (0.50) | HTTALOX5SIGMAR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3988521 | 0.83 | ALOX5 (0.62) | HTTALOX5ALDH1A1SMN1; SMN2CYP3A4 | |
| SCHEMBL38660988 | 0.82 | HDAC4 (0.46) | HTTALOX5ALDH1A1HDAC4HDAC6 | |
| SCHEMBL13536796 | 0.82 | HDAC4 (0.48) | ALOX5SIGMAR1HDAC4HDAC6CYP3A4 | |
| SCHEMBL1399311 | 0.82 | TDP1 (0.56) | HTTALDH1A1SMN1; SMN2GAACTBP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6897231-B2 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, INC. (US) | 2005-05-24 | — | — | US | claimed |
| WO-2026101698-A1 | HEPCIDIN MIMETIC COMPOUNDS AND USES THEREOF | PROTAGONIST THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20130158031-A1 | ALKYNE-BRIDGED HETERO-AROMATICS AND USES THEREOF | SU ZHOU JING HONG BIOTECH CO., LTD. (CN) | 2013-06-20 | — | — | US | disclosed |
| US-20130158031-A1 | ALKYNE-BRIDGED HETERO-AROMATICS AND USES THEREOF | SU ZHOU JING HONG BIOTECH CO., LTD. (CN) | 2013-06-20 | — | — | US | disclosed |
| US-20130158031-A1 | ALKYNE-BRIDGED HETERO-AROMATICS AND USES THEREOF | SU ZHOU JING HONG BIOTECH CO., LTD. (CN) | 2013-06-20 | — | — | US | disclosed |
| EP-1981877-B1 | N-HYDROXYACRYLAMIDE COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2012-04-18 | — | — | EP | disclosed |
| US-7750155-B2 | Pyrazinyl hydroxyacrylamide compounds having an inhibitory effect on the activity of histone deacetylase | ASTELLAS PHARMA INC. (JP) | 2010-07-06 | — | — | US | disclosed |
| US-20090326018-A1 | 2-Phenyl indene derivatives useful as estrogen receptor ligands | KARO BIO AB (SE) | 2009-12-31 | — | — | US | disclosed |
| US-20090326018-A1 | 2-Phenyl indene derivatives useful as estrogen receptor ligands | KARO BIO AB (SE) | 2009-12-31 | — | — | US | disclosed |
| US-20090326018-A1 | 2-Phenyl indene derivatives useful as estrogen receptor ligands | KARO BIO AB (SE) | 2009-12-31 | — | — | US | disclosed |
| WO-2008043567-A1 | 2-PHENYL INDENE DERIVATIVES USEFUL AS ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008043567-A1 | 2-PHENYL INDENE DERIVATIVES USEFUL AS ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2008-04-17 | — | — | WO | disclosed |
| WO-2007091703-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2007-08-16 | — | — | WO | disclosed |
| US-6881736-B1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2005-04-19 | — | — | US | disclosed |
| US-6881736-B1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2005-04-19 | — | — | US | disclosed |
| EP-1218005-B1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2004-12-15 | — | — | EP | disclosed |
| US-20030220377-A1 | Indole compounds and their use as estrogen agonists/antagonists | CHESWORTH RICHARD (US) | 2003-11-27 | — | — | US | disclosed |
| EP-1218005-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2002-10-09 | — | — | EP | disclosed |
| EP-1218005-A2 | VITRONECTIN RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001017959-A2 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220377-A1 | Indole compounds and their use as estrogen agonists/antagonists | ESR1, GPER1, ESR2 | HTT 1345/4885ALOX5 653/4885SIGMAR1 433/4885 |
| US-20130158031-A1 | ALKYNE-BRIDGED HETERO-AROMATICS AND USES THEREOF | CHRNA10, ATXN10, SCN10A | HTT 18/4885ALOX5 1549/4885SIGMAR1 341/4885 |
| US-20090326018-A1 | 2-Phenyl indene derivatives useful as estrogen receptor ligands | ESR1, GPER1, ESR2 | HTT 4114/4885ALOX5 1708/4885SIGMAR1 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.